

ASX Release

\$500,000 NON-DILUTIVE FINANCE FACILITY AGREEMENT WITH VICTORIAN GOVERNMENT**HIGHLIGHTS**

- **TALi granted \$500,000 non-dilutive Research and Development (R&D) funding facility with Invest Victoria**
- **Facility relates to FY2022 R&D and is in addition to R&D rebate received for the FY2021 period**
- **Enhances cash position and enables TALi to accelerate near-term commercialisation milestones**

TALi Digital Ltd (ASX: TD1, “**TALi**” or “**the Company**”), a leading global digital health business advises that it has executed a \$500,000 non-dilutive funding facility (Facility) with Treasury Corporation of Victoria (TCV) as part of the Victorian Government’s R&D Cash Flow Loan Initiative (Initiative).

The Facility will be received in two tranches: the first of \$300,000 has been received; and the second of up to A\$203,744 in the quarter ending 31 March 2022. The funds will be used on commercialisation activities including those activities that support the agreement between Akili Interactive Labs Inc. (“Akili”) and TALi ([full ASX release here](#)). The agreement with Akili has significant expected milestone payments to TALi attached to it and delivery of milestones ahead of schedule would expedite revenues to TALi from the agreement.

The Victorian Government’s R&D Cash Flow Loan Initiative is administered by Invest Victoria. It is designed to support innovative Victorian small to medium enterprises (SMEs) who are investing in research and development activity to develop the products, services and technologies vital to the State’s future economy. The Initiative offers low-interest loans of A\$0.25-4.0 million on up to 80% of an SME’s forecasted Research & Development Tax Incentive (RDTI) rebate for the period ending 30 June 2022. Interest on Facility advances is variable at the “TCV 11am” loan interest rate (currently 0.265%). Repayment of the Facility is timed to coincide with receipt of the TALi FY2023 R&D Tax offset, expected by 31 October 2023, but may be repaid earlier. The Facility is secured by the FY2022 and FY2023 RDTI refund.

Release authorised by:

The Board of TALi Digital Limited

CONTACT

Corporate

Glenn Smith
TALi Digital Managing Director
1300 082 013
investors@talidigital.com

Investors

Bellevue Investor Relations
Katie Mackenzie
0455 502 197
kmackenzie@bellevueir.com.au

Catherine Ross
0421 997 481
catherine@irconsult.com.au

About TALi Digital

TALi [TALi Digital Limited (ASX: TD1)] is a digital health company delivering diagnostic and therapeutic solutions to enhance cognitive function and behaviour. The Company has built a patented platform technology with our first solution targeting cognitive attention skills during early childhood via the evidence and game-based screening (DETECT®) and training (TRAIN®) modules. This program is complementary to existing diagnosis and therapy and places TALi at the forefront of patient experience and early intervention for attention related conditions.

A continuous innovation focus will see the Company deliver a series of product developments in ADHD (Attention Deficit Hyperactivity Disorder) and ASD (Autism Spectrum Disorder) along with a core research program exploring applications for at populations afflicted with Mild Cognitive Decline (MCI has been found to often been a precursor to recognizing Alzheimer's disease and other forms of dementia).

At TALi, our vision is to deliver a personalised digital experience to enhance cognitive care. Learn more at talidigital.com.